Partial Beclin 1 silencing aggravates doxorubicin- and Fas-induced apoptosis in HepG2 cells

Figure 3 Percentage of subG1 cells after treatment of siRNA-transfected HepG2 cells with an agonistic anti-Fas antibody or doxorubicin. A: Representative flow cytometry analysis of the cell cycle; B: Quantification of the subG1 peak. Results are means ± SE for 5 to 8 experiments (^aP < 0.05 vs untreated cells; ^cP < 0.05 vs cells transfected with the control siRNA); C: Effects of z-VAD-fmk. The figure shows the mean percent decrease in subG1 cells for 3 to 5 experiments (^eP < 0.05 between cells incubated with and without z-VAD-fmk).